Cargando…
Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
Whilst the global prevalence of haemophilia B is less than that of haemophilia A, rapid and remarkable innovations have been made in the development of haemophilia B therapies in the last decade. The most recent developments are the evolution of extended half-life haemophilia B replacement therapies...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196631/ https://www.ncbi.nlm.nih.gov/pubmed/30364483 http://dx.doi.org/10.1177/2040620718802606 |